Cellectar Biosciences (CLRB)

The company’s lead program is iopofosine, also known as CLR 131, a small-molecule PDC that delivers a radioisotope payload. It has been studied in hematologic cancers and solid tumors, with particular attention to rare or difficult-to-treat indications where targeted radiotherapeutics may offer a differentiated approach. Cellectar also lists additional PDC candidates, including CLR 121125 and CLR 121225, as part of a pipeline intended to show the flexibility of the platform across different payloads and cancer types.

As a development-stage biopharmaceutical business, Cellectar’s value depends heavily on clinical trial results, regulatory progress, access to capital, and the commercial potential of any approved therapy. The company reports its operations as a single segment focused on applying the PDC platform to oncology drug development. For investors, CLRB represents exposure to a specialized cancer-drug platform rather than a diversified pharmaceutical business, with the high risk and potential upside typical of small clinical-stage biotech companies.